EP1368335A2 - Nouveaux derives d'acide aminodicarbonique presentant des proprietes pharmaceutiques - Google Patents
Nouveaux derives d'acide aminodicarbonique presentant des proprietes pharmaceutiquesInfo
- Publication number
- EP1368335A2 EP1368335A2 EP02701292A EP02701292A EP1368335A2 EP 1368335 A2 EP1368335 A2 EP 1368335A2 EP 02701292 A EP02701292 A EP 02701292A EP 02701292 A EP02701292 A EP 02701292A EP 1368335 A2 EP1368335 A2 EP 1368335A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- carbon atoms
- chain
- straight
- branched
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Definitions
- the present invention relates to new chemical compounds which also stimulate soluble guanylate cyclase via a novel mode of action which does not involve the heme group of the enzyme, their production and their use as medicaments, in particular as medicaments for the treatment of cardiovascular diseases.
- Cyclic guanosine monophosphate is one of the most important cellular transmission systems in mammalian cells. Together with nitrogen monoxide (NO), which is released from the endothelium and transmits hormone-like and mechanical signals, it forms the NO / cGMP system.
- NO nitrogen monoxide
- the guanylate cyclases catalyze the biosynthesis of cGMP from guanosine triposphate (GTP).
- GTP guanosine triposphate
- the previously known representatives of this family can be divided into two groups according to structural features and the type of ligand: the particulate guanylate cyclases that can be stimulated by natriuretic peptides and the soluble guanylate cyclases that can be stimulated by NO.
- the soluble guanylate cyclases consist of two subunits and most likely contain one heme per heterodimer, which is part of the regulatory center. This is of central importance for the activation mechanism. NO can bind to the iron atom of the heme and thus significantly increase the activity of the enzyme. Hem-free preparations, on the other hand, cannot be stimulated by NO. CO is also able to attack the central iron atom of the heme, whereby the stimulation by CO is significantly less than that by NO.
- guanylate cyclase plays a decisive role in different physiological processes, in particular in the relaxation and proliferation of smooth muscle cells, platelet aggregation and adhesion and neuronal signal transmission as well as in diseases , which are based on a disturbance of the above-mentioned processes.
- the NO / cGMP system can be suppressed, which leads to Examples include high blood pressure, platelet activation, increased cell proliferation, endothelial dysfunction, atherosclerosis, angina pectoris, heart failure, thrombosis, stroke and myocardial infarction.
- a NO-independent treatment option for such diseases aimed at influencing the cGMP signal path in organisms is a promising approach due to the expected high efficiency and few side effects.
- the previously known stimulators of soluble guanylate cyclase stimulate the enzyme either directly via the heme group (carbon monoxide, nitrogen monoxide or diphenyliodonium hexafluorophosphate) by interaction with the iron center of the heme group and a resulting conformational change that leads to an increase in enzyme activity (Gerzer et al., FEBS Lett. 132 (1981), 71), or via a heme-dependent mechanism that is independent of NO, but too potentiates the stimulating effect of NO or CO (e.g. YC-1, Hoenicka et al., J. Mol. Med. (1999) 14; or that in WO 98/16223, WO 98/16507 and WO 98/23619 described pyrazole derivatives).
- NO or CO e.g. YC-1, Hoenicka et al., J. Mol. Med. (1999) 14; or that in WO 98/16223, WO 98/
- Fatty acids such as B. arachidonic acid, prostaglandin endoperoxides and fatty acid hydroperoxides on the soluble guanylate cyclase could not be confirmed (see e.g. Hoenicka et al., J. Mol. Med. 77 (1999), 14).
- the enzyme still shows a detectable catalytic basal activity, i.e. cGMP is still formed.
- the remaining catalytic basal activity of the heme-free enzyme cannot be stimulated by any of the known stimulators mentioned above.
- protoporphyrin IX A stimulation of heme-free soluble guanylate cyclase by protoporphyrin IX has been described (Ignarro et al., Adv. Pharmacol. 26 (1994), 35).
- protoporphyrin IX can be regarded as facial expressions for the NO-heme adduct, which is why the addition of protoporphyrin IX to the soluble guanylate cyclase should lead to the formation of a structure of the enzyme corresponding to the soluble guanylate cyclase which is stimulated by NO. This is also through the
- the compounds according to the invention are able to stimulate both the heme-containing and the heme-free form of the soluble guanylate cyclase.
- the stimulation of the enzyme with these new stimulators is via a heme-independent path, which is also demonstrated by the fact that the new stimulators on the heme-containing enzyme on the one hand show no synergistic effect with NO and on the other hand the effect of these new stimulators is not affected by Hem-dependent inhibitor of soluble guanylate cyclase, lH-l, 2,4-oxadiazol- (4,3a) -quinoxalin-l-one (ODQ).
- EP-A-0 345 068 describes, inter alia, the aminoalkanecarboxylic acid (1) as an intermediate in the synthesis of GABA antagonists:
- WO 93/00359 describes the aminoalkanecarboxylic acid (2) as an intermediate in peptide synthesis and its use as an active ingredient for treating diseases of the central nervous system:
- Row S, N and / or O is fused, or a partially unsaturated or aromatic heterocycle having 1 to 9 carbon atoms and up to 3
- V is absent, O, NR 4 , NR 4 CONR 4 , NR 4 CO, NR 4 SO 2 , COO, CONR 4 or S (O) 0 ,
- o 0, 1 or 2
- Q is missing, straight chain or branched alkylene, straight chain or branched
- Means alkenediyl or straight-chain or branched alkynediyl each having up to 12 carbon atoms, each of which has one or more groups from O, S (O) p , NR 5 , CO, NR 5 SO 2 or CONR 5 can contain, and can be substituted one or more times by halogen, hydroxy or alkoxy with up to 4 carbon atoms, optionally any two atoms of the above chain to form a three- to eight-membered ring can be connected to one another,
- R 5 denotes hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms or cycloalkyl having 3 to 8 carbon atoms, which can be substituted by halogen or alkoxy having up to 4 carbon atoms,
- R 6 is hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms, straight-chain or branched haloalkyl having up to 8 carbon atoms or cycloalkyl having 3 to 8 carbon atoms,
- R 8 , R 9 , R 11 and R 12 independently of one another are hydrogen, straight-chain or branched alkyl, straight-chain or branched alkenyl having up to 8 carbon atoms, aryl having 6 to 10 carbon atoms, an aromatic heterocycle having 1 to 9 carbon atoms and up to 3 heteroatoms from the series S, N and / or O, arylalkyl with 8 to 18
- R denotes straight-chain or branched alkyl having up to 4 carbon atoms or aryl having 6 to 10 carbon atoms, the aryl radical in turn can be substituted one or more times by halogen, CN, NO 2 , alkyl, alkoxy, haloalkyl or haloalkoxy having up to 6 carbon atoms,
- R 10 is hydrogen, straight-chain or branched alkyl having up to 12 carbon atoms, straight-chain or branched alkenyl having up to 12 carbon atoms, aryl having 6 to 10 carbon atoms, an aromatic heterocycle having 1 to 9 carbon atoms and up to 3 heteroatoms from the series S, N and or denotes O or cycloalkyl having 3 to 8 carbon atoms, which may optionally further be substituted by halogen, hydroxy, CN, NO 2 , NH 2 , NHCOR 7 , alkyl, alkoxy, haloalkyl or haloalkoxy having up to 6 carbon atoms;
- aryl with 6 to 10 carbon atoms, a saturated carbocycle with 6 to 10 carbon atoms, an aromatic or saturated heterocycle with 1 to 9 carbon atoms and up to 3 heteroatoms from the series S, N and / or O can be substituted, which can also be bonded via N, which is directly or via a group from O, S, SO, SO 2 , NR 7 , SO 2 NR 7 , CON, straight-chain or branched alkylene, straight-chain or branched alkenediyl , straight-chain or branched alkyloxy, straight-chain or branched oxyalkyloxy, straight-chain or branched sulfonylalkyl, straight-chain or branched thioalkyl, each with up to 8
- Carbon atoms can be bonded and one to three times by straight-chain or branched alkyl, straight-chain or branched alkoxy, straight-chain or branched alkoxyalkoxy, straight-chain or branched haloalkyl, straight-chain or branched haloalkoxy, carbonylalkyl or straight-chain or branched alkenyl, each with up to 6 Carbon atoms, halogen, SR 6 , CN, NO 2 , NR 8 R 9 , CONR 15 R 16 or NR 14 COR 17 can be substituted,
- R 15 , R 16 independently of one another are hydrogen, straight-chain or branched
- R 17 is hydrogen, straight-chain or branched alkyl with up to 12
- Haloalkyl or haloalkoxy can be substituted with up to 6 carbon atoms
- the cyclic radicals can be fused with an aromatic or saturated carbocycle with 1 to 10 carbon atoms or an aromatic or saturated heterocycle with 1 to 9 carbon atoms and up to 3 heteroatoms from the series S, N and / or O,
- C 6 - alkoxy, NR 19 R 20 , cycloalkyl with 3 to 8 carbon atoms can carry, straight-chain or branched haloalkyl, straight-chain or branched alkoxy, or alkoxycarbonyl with up to 4 carbon atoms each, CN, NO 2 , NR 19 R 20 , SR 17 , SO 2 R 17 , cycloalkyl with 3 to 8 carbon atoms, haloalkoxy haloalkoxy with up to 6 carbon atoms,
- Cycloalkoxy with up to 14 carbon atoms CONH 2 , CONR 17 R 17 , SO 2 NH 2 , SO 2 NR 17 R 17 , alkoxyalkoxy with up to 12 carbon atoms, NHCOOR 17 , NHCOR 17 , NHSO 2 R 17 , NHCONH 2 , OCONR 17 R 17 , OSO 2 R 17 , C 2 -i 2 -alkenyl or C ⁇ .i 2 -alkynyl means
- R 19 and R 20 independently of one another are hydrogen, straight-chain or branched alkyl having up to 4 carbon atoms or cycloalkyl having 3 to 8 carbon atoms, m represents an integer from 1 to 4,
- W denotes straight-chain or branched alkylene with up to 6 carbon atoms or straight-chain or branched alkenediyl with up to 6 carbon atoms, each of which can contain a group from O, S (O) q , NR 21 , CO or CONR 21 , or CO, NHCO or OCO means
- q 0, 1 or 2
- U denotes straight-chain or branched alkyl having up to 4 carbon atoms
- A is aryl with 6 to 10 carbon atoms or an aromatic heterocycle with 1 to 9 carbon atoms and up to 3 heteroatoms from the series S, N and / or O, which may be one to three times by halogen, straight-chain or branched alkyl, straight-chain or branched Haloalkyl, straight-chain or branched alkoxy, haloalkoxy or alkoxycarbonyl with up to 4 carbon atoms, CN, NO 2 or NR 22 R 23 can be substituted, in which
- R and R each independently represent hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms or cycloalkyl having 3 to 8 carbon atoms, carbonylalkyl or sulfonylalkyl.
- R 2 means tetrazolyl, COOR 24 or CONR 25 R 26 ,
- R 24 is hydrogen, alkyl of 1 to 8 carbon atoms or cycloalkyl of 3 to 8 carbon atoms
- R 25 and R 26 each independently represent hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms, cycloalkyl having 3 to 8 carbon atoms or a radical of the formula SO 2 R 27 , or R 25 and R 26 together represent a five- or six-membered ring form, which can contain N or O,
- R 27 denotes straight-chain or branched alkyl having up to 4 carbon atoms or aryl having 6 to 10 carbon atoms, the aryl radical in turn being one or more times by halogen, CN, NO 2 , alkyl, alkoxy, haloalkyl or haloalkoxy having up to 6
- X denotes straight-chain or branched alkylene with up to 12 carbon atoms or straight-chain or branched alkenediyl with up to 12 carbon atoms, each of one to three groups from O, S (O) r , NR 28 , CO or
- CONR 29 may contain aryl or aryloxy having 6 to 10 carbon atoms, the aryl radical in turn being able to be substituted one or more times by halogen, CN, NO, alkyl, alkoxy, haloalkyl or haloalkoxy having up to 6 carbon atoms, optionally two random atoms of the above chains are connected to one another by an alkyl chain to form a three- to eight-membered ring, embedded image in which
- r 0, 1 or 2
- R 28 represents hydrogen, alkyl having 1 to 8 carbon atoms or cycloalkyl having 3 to 8 carbon atoms,
- R 29 denotes hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms or cycloalkyl having 3 to 8 carbon atoms,
- n 1 or 2;
- R 1 means tetrazolyl, COOR 30 or CONR 31 R 32 ,
- R 30 is hydrogen, alkyl of 1 to 8 carbon atoms or cycloalkyl of 3 to 8 carbon atoms
- R 31 and R 32 each independently represent hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms, cycloalkyl having 3 to 8 carbon atoms or a radical of the formula SO 2 R 33 ,
- R means straight-chain or branched alkyl having up to 4 carbon atoms or aryl having 6 to 10 carbon atoms, the aryl radical in turn can be substituted one or more times by halogen, CN, NO 2 , alkyl, alkoxy, haloalkyl or haloalkoxy having up to 6 carbon atoms,
- radicals V and W can be bonded to any carbon atom or to any nitrogen atom of a ring which may be present;
- V is absent, O, NR 4 , NR 4 CONR 4 , NR 4 CO, NR 4 SO 2 , COO, CONR 4 or S (O) 0 ,
- R 4 independently of any further radical R 4 which may be present, denotes hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms, cycloalkyl having 3 to 8 carbon atoms, aryl having 6 to 10 carbon atoms or arylalkyl having 7 to 18 carbon atoms, the aryl radical can in turn be substituted one or more times by halogen, alkyl, alkoxy having up to 6 carbon atoms,
- Q is absent, straight-chain or branched alkylene, straight-chain or branched alkenediyl or straight-chain or branched alkynediyl each having up to 12 carbon atoms, each of which means one or more groups of O, S (O) p , NR 5 , CO, NR 5 SO 2 or CONR 5 can contain, and can be substituted one or more times by halogen, hydroxy or alkoxy with up to 4 carbon atoms, optionally any two atoms of the above chain can be connected to form a three- to eight-membered ring,
- R 5 is hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms or cycloalkyl having 3 to 8 carbon atoms, which can be substituted by halogen or alkoxy having up to 4 carbon atoms,
- p 0, 1 or 2
- Y is hydrogen, NR 8 R 9 , aryl with 6 to 10 carbon atoms, an aromatic or saturated heterocycle with 1 to 9 carbon atoms and up to 3 heteroatoms from the series S, N and / or O or straight-chain or branched cycloalkyl with 3 to 8 carbon atoms, which can also be bonded via N, the cyclic radicals in each case one to three times by straight-chain or branched alkyl, straight-chain or branched alkenyl, straight-chain or branched alkynyl, straight-chain or branched alkoxy, straight-chain or branched alkoxyalkoxy, straight-chain or branched Haloalkyl, straight-chain or branched haloalkoxy each having up to 8 carbon atoms, straight-chain or branched cycloalkyl having 3 to 8 carbon atoms, halogen, hydroxy, CN, SR 6 , NO 2 , NR 8 R 9 , NR 7 COR 10
- NR 7 CONR 7 R 10 or CONR ⁇ R 12 can be substituted, embedded image in which
- R 6 denotes hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms, straight-chain or branched haloalkyl having up to 8 carbon atoms or cycloalkyl having 3 to 8 carbon atoms,
- R 7 independently of any further radical R 7 which may be present, denotes hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms or cycloalkyl having 3 to 8 carbon atoms,
- R 8 , R 9 , R 11 and R 12 independently of one another are hydrogen, straight-chain or branched alkyl, straight-chain or branched alkenyl with up to
- R 13 denotes straight-chain or branched alkyl having up to 4 carbon atoms or aryl having 6 to 10 carbon atoms, the aryl radical in turn being used one or more times by halogen, CN, NO 2 , alkyl, alkoxy, haloalkyl or haloalkoxy having up to 6 carbon atoms can be substituted
- R 10 is hydrogen, straight-chain or branched alkyl having up to 12 carbon atoms, straight-chain or branched alkenyl having up to
- Haloalkyl or haloalkoxy can be substituted with up to 6 carbon atoms
- Haloalkyl, straight-chain or branched haloalkoxy, carbonylalkyl or straight-chain or branched alkenyl having in each case up to 6 carbon atoms, halogen, SR 6, CN, NO 2, NR 8 R 9, CONR l5 R 16 or NR 14 COR 17 may be substituted,
- R 14 denotes hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms or cycloalkyl having 3 to 8 carbon atoms,
- R 15 , R 16 independently of one another are hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms, cycloalkyl having 3 to 8 carbon atoms or a radical of the formula SO 2 R 18 ,
- R 18 denotes straight-chain or branched alkyl having up to 4 carbon atoms or aryl having 6 to 10 carbon atoms, the aryl radical in turn being substituted one or more times by halogen, CN, NO 2 , alkyl, alkoxy, haloalkyl or haloalkoxy having up to 6 carbon atoms can
- R 17 is hydrogen, straight-chain or branched alkyl with up to 12
- 3 heteroatoms from the series S, N and / or O or cycloalkyl with 3 is up to 8 carbon atoms, which may optionally be further substituted by halogen, CN, NO 2 , alkyl, alkoxy, haloalkyl or haloalkoxy having up to 6 carbon atoms;
- Carbocycle with 1 to 10 carbon atoms or an aromatic or saturated heterocycle with 1 to 9 carbon atoms and up to 3 heteroatoms from the series S, N and / or O can be fused
- R 3 denotes hydrogen, halogen, straight-chain or branched alkyl, straight-chain or branched haloalkyl or straight-chain or branched alkoxy each having up to 4 carbon atoms,
- n an integer from 1 to 4,
- W denotes straight-chain or branched alkylene or straight-chain or branched alkenediyl each having up to 4 carbon atoms
- A is phenyl or an aromatic heterocycle having 1 to 9 carbon atoms and up to 3 heteroatoms from the series S, N and / or O, which may be one to three times by halogen, straight-chain or branched alkyl, straight-chain or branched haloalkyl or straight-chain or branched alkoxy with up to 4 carbon atoms, can be substituted,
- R 2 means COOR 24
- X denotes straight-chain or branched alkylene with up to 8 carbon atoms or straight-chain or branched alkenediyl with up to 8 carbon atoms, each of one to three groups from phenyl, phenyloxy, O, CO
- R 29 denotes hydrogen, straight-chain or branched alkyl having up to 6 carbon atoms or cycloalkyl having 3 to 6 carbon atoms,
- n 1 or 2;
- R 1 means COOR 30 ,
- R, 30 is hydrogen or straight-chain or branched alkyl having up to 6 carbon atoms.
- radicals V and W can be bonded to any carbon atom or to any nitrogen atom of a ring which may be present;
- V is absent, O, S or NR 4 means
- R represents hydrogen or methyl
- cyclic radicals are each one to three times by straight-chain or branched alkyl, straight-chain or branched alkenyl, straight-chain or branched alkynyl, straight-chain or branched alkoxy, straight-chain or branched alkoxyalkoxy, straight-chain or branched haloalkyl, straight-chain or branched haloalkoxy each having up to 4 carbon atoms, straight-chain or branched cycloalkyl having 3 to 6 carbon atoms, F, CI, Br, I, NO 2 , SR 6 , NR 8 R 9 , NR 7 COR 10 or CONR ⁇ R 12 substituted could be,
- R denotes hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms, or straight-chain or branched haloalkyl having up to 4 carbon atoms,
- R 7 denotes hydrogen, or straight-chain or branched alkyl having up to 4 carbon atoms
- R 8 , R 9 , R 11 and R 12 independently of one another are hydrogen, straight-chain or branched alkyl having up to 4 carbon atoms, or phenyl, where the phenyl radical is monosubstituted to triple by F, CI Br, hydroxy, methyl, ethyl, n - Propyl, i-propyl, n-butyl, s-butyl, i-butyl, t-butyl, Methoxy, ethoxy, amino, acetylamino, NO 2 , CF 3 , OCF 3 or CN may be substituted, or two substituents from R 8 and R 9 or R 11 and R 12 may be linked to form a five- or six-membered ring, which can be interrupted by O or N,
- R 14 denotes hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms or cycloalkyl having 3 to 8 carbon atoms,
- R 17 is hydrogen, straight-chain or branched alkyl having up to 12 carbon atoms, straight-chain or branched alkenyl having up to
- Butyl, i-butyl, t-butyl, methoxy, ethoxy, amino, acetylamino, NO 2 , CF 3 , OCF 3 or CN may be substituted;
- R 3 represents hydrogen, methyl or fluorine
- n an integer from 1 to 4,
- W denotes CH 2 , -CH 2 CH 2 -, CH 2 CH 2 CH 2)
- CH CHCH 2 ,
- A is phenyl, pyridyl, thienyl or thiazolyl, which is optionally one to three times by methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, CF 3 , methoxy, Ethoxy, F, CI, Br can be substituted,
- R 2 means COOR 24
- R 24 is hydrogen or straight-chain or branched alkyl with up to 4
- X denotes straight-chain or branched alkylene with up to 8 carbon atoms or straight-chain or branched alkenediyl with up to 8 carbon atoms, each of which may contain one to three groups from phenyl, phenyloxy, O, CO or CONR 30 ,
- R 30 denotes hydrogen, straight-chain or branched alkyl having up to 6 carbon atoms or cycloalkyl having 3 to 6 carbon atoms
- n 1 or 2;
- R 1 means COOR 35 ,
- R 35 is hydrogen or straight-chain or branched alkyl having up to 6 carbon atoms.
- radicals V and W can be bonded to any carbon atom or to any nitrogen atom of a ring which may be present;
- the cyclic radicals in each case one to three times by straight-chain or branched alkyl, straight-chain or branched alkenyl, straight-chain or branched alkynyl, straight-chain or branched alkoxy, straight-chain or branched alkoxyalkoxy, straight-chain or branched haloalkyl, straight-chain or branched haloalkoxy with in each case up to 4 carbon atoms, straight-chain or branched cycloalkyl with 3 to 6 carbon atoms, F, CI, Br, I, NO 2 , SR 6 , NR 8 R 9 , NR 7 COR 10 or CONR n R 12 can be substituted, embedded image in which
- R 6 denotes hydrogen, straight-chain or branched alkyl having up to 4 carbon atoms, or straight-chain or branched haloalkyl having up to 4 carbon atoms,
- R 7 denotes hydrogen, or straight-chain or branched alkyl having up to 4 carbon atoms
- R 8 , R 9 , R 11 and R 12 independently of one another are hydrogen, straight-chain or branched alkyl having up to 4 carbon atoms, or phenyl, where the phenyl radical is monosubstituted to triple by F, CI Br, hydroxy, methyl, ethyl, n - Propyl, i-propyl, n-butyl, s-butyl, i-butyl, t-butyl,
- R 10 is hydrogen, straight-chain or branched alkyl having up to 4 carbon atoms, or phenyl, where the phenyl radical is monosubstituted to triple by F, Cl Br, hydroxy, methyl, ethyl, n-propyl, i-propyl, n-butyl, see -Butyl, i-butyl, t-butyl,
- Methoxy, ethoxy, amino, acetylamino, NO 2 , CF 3 , OCF 3 or CN may be substituted;
- R 17 is hydrogen, straight-chain or branched alkyl having up to 6 carbon atoms, straight-chain or branched alkenyl having up to
- Butyl, i-butyl, t-butyl, methoxy, ethoxy, amino, acetylamino, NO 2 , CF 3 , OCF 3 or CN may be substituted;
- the cyclic radicals can be fused with an aromatic or saturated carbocycle with 1 to 10 carbon atoms or an aromatic or saturated heterocycle with 1 to 9 carbon atoms and up to 3 heteroatoms from the series S, N and / or O,
- R represents hydrogen, methyl or fluorine
- n an integer from 1 to 2
- W -CH 2 - or -CH 2 CH 2 - means
- A is phenyl, which is optionally one to three times by methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, CF 3 , methoxy, ethoxy, F, CI, Br can be substituted
- R 2 means COOR 24 embedded image in which
- R 24 denotes hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms
- R 30 denotes hydrogen, straight-chain or branched alkyl having up to 6 carbon atoms or cycloalkyl having 3 to 6 carbon atoms,
- n 1 or 2;
- R 1 means COOR 35 ,
- R 35 is hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms.
- radicals V and W can be bonded to any carbon atom or to any nitrogen atom of a ring which may be present;
- Y is phenyl which is substituted by a radical selected from the group consisting of 2-phenylethyl, cyclohexyl, 4-chlorophenyl, 4-methoxyphenyl,
- R 3 represents hydrogen, methyl or fluorine
- n an integer from 1 to 2
- A means phenyl
- R 2 means COOH, where R 2 is in the 4-position to the rest U,
- X means (CH 2 )
- R 1 means COOH. Also particularly preferred according to the present invention are compounds in which
- radicals V and W can be bonded to any carbon atom or to any nitrogen atom of a ring which may be present;
- Q means CH 2 O which is bonded to Z via its carbon atom
- Y is phenyl which is substituted by a radical selected from the group consisting of 2-phenylethyl, cyclohexyl, 4-chlorophenyl, 4-methoxyphenyl, 4-trifmormethylphenyl, 4-cyanophenyl, 4-chlorophenoxy, 4-methoxyphenoxy, 4-trifluoromethylphenoxy, 4-cyanophenoxy, 4-methylphenyl, 4-tert-butylphenyl, 4-carboxyphenyl, 4-fluorophenyl, 3-methoxyphenyl, 2,4-dichlorophenyl is selected,
- R 3 represents hydrogen, methyl or fluorine
- n an integer from 1 to 2
- A means phenyl
- R means COOH, where R2 is arranged in 4 position to the rest U,
- R 1 means COOH.
- the compounds of the general formula (I) according to the invention can also be present in the form of their salts. In general, salts with organic or inorganic bases or acids may be mentioned here.
- Physiologically acceptable salts are preferred in the context of the present invention.
- Physiologically acceptable salts of the compounds according to the invention can be salts of the substances according to the invention with mineral acids, carboxylic acids or sulfonic acids.
- Physiologically acceptable salts of the compounds according to the invention can be salts of the substances according to the invention with mineral acids, carboxylic acids or sulfonic acids.
- particular preference is given to Salts with hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, naphthalenedisulfonic acid, acetic acid, propionic acid, lactic acid, tartaric acid, citric acid, fumaric acid, maleic acid or benzoic acid.
- Physiologically acceptable salts can also be metal or ammonium salts of the compounds according to the invention which have a free carboxyl group.
- Sodium, potassium, magnesium or calcium salts as well as ammonium salts derived from ammonia, or organic amines such as ethylamine, di- or triethylamine, di- or triethanolamine, dicyclohexylamine, dimethylaminoethanol, arginine, lysine or ethylenediamine.
- the compounds according to the invention can exist in stereoisomeric forms which either behave like image and mirror image (enantiomers) or do not behave like image and mirror image (diastereomers).
- the invention relates both to the enantiomers or diastereomers and to their respective mixtures.
- the racemic forms can be separated into the stereoisomerically uniform constituents in a known manner, for example by racemate resolution or chromatographic separation.
- Double bonds present in the compounds according to the invention can be in the eis or trans configuration (Z or E form).
- the substituents generally have the following meaning:
- Alkyl generally represents a straight-chain or branched hydrocarbon radical having 1 to 20 carbon atoms.
- Alkylene generally stands for a straight-chain or branched hydrocarbon bridge with 1 to 20 carbon atoms.
- methylene ethylene
- ethylene ethylene
- Alkenyl generally represents a straight-chain or branched hydrocarbon radical having 2 to 20 carbon atoms and one or more, preferably one or two, double bonds. Examples include allyl, propenyl, isopropenyl, butenyl, isobutenyl, pentenyl, isopentenyl, hexenyl, isohexenyl, heptenyl, isoheptenyl, octenyl and isooctenyl.
- Alkynyl generally represents a straight-chain or branched hydrocarbon radical having 2 to 20 carbon atoms and one or more, preferably with one or two triple bonds. Examples include ethynyl, 2-butynyl, 2-pentynyl and 2-hexynyl.
- Alkenediyl generally represents a straight-chain or branched hydrocarbon bridge with 2 to 20 carbon atoms and one or more, preferably with one or two, double bonds.
- Alkenediyl generally represents a straight-chain or branched hydrocarbon bridge with 2 to 20 carbon atoms and one or more, preferably with one or two, double bonds.
- Alkindiyl generally represents a straight-chain or branched hydrocarbon bridge with 2 to 20 carbon atoms and one or more, preferably with one or two triple bonds. Examples include ethyne-1,2-diyl, propyne-1,3-diyl, l-butyne-1,4-diyl, l-butyne-1,3-diyl, 2-butene-1,4-diyl.
- Acyl generally represents straight-chain or branched lower alkyl having 1 to 9 carbon atoms, which is bonded via a carbonyl group. Examples include: acetyl, ethylcarbonyl, propylcarbonyl, isopropylcarbonyl, butylcarbonyl and isobutylcarbonyl.
- Alkoxy generally represents a straight-chain or branched hydrocarbon radical having 1 to 14 carbon atoms which is bonded via an oxygen atom. Examples include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, pentoxy, isopentoxy, hexoxy, isohex oxy, heptoxy, isoheptoxy, octoxy or iso-octoxy.
- alkoxy and “alkyloxy” are used synonymously.
- Alkoxyalkyl generally represents an alkyl radical having up to 8 carbon atoms which is substituted by an alkoxy radical having up to 8 carbon atoms.
- Alkyl here generally represents a straight-chain or branched hydrocarbon radical having 1 to 13 carbon atoms. Examples include the following alkoxycarbonyl radicals: methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl or isobutoxycarbonyl.
- Cycloalkyl generally represents a cyclic hydrocarbon radical having 3 to 8 carbon atoms. Cyclopropyl, cyclopentyl and cyclohexyl are preferred. Examples include cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
- Cycloalkoxy in the context of the invention is an alkoxy radical whose hydrocarbon radical is a cycloalkyl radical.
- the cycloalkyl radical generally has up to 8 carbon atoms. Examples include: cyclopropyloxy and cyclohexyloxy.
- the terms "cycloalkoxy” and “cycloalkyloxy” are used synonymously.
- Aryl generally represents an aromatic radical having 6 to 10 carbon atoms.
- Preferred aryl radicals are phenyl and naphthyl.
- Halogen in the context of the invention represents fluorine, chlorine, bromine and iodine.
- heterocycle generally represents a saturated, unsaturated or aromatic 3- to 10-membered, for example 5- or 6-membered, heterocycle which can contain up to 3 heteroatoms from the series S, N and or or and which in the case of a nitrogen atom can also be bound via this.
- heterocycle includes: oxadiazolyl, thiadiazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, thienyl, furyl, pyrrolyl, pyrrolidinyl, piperazinyl,
- Thiazolyl, furyl, oxazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidinyl, pyridazinyl and tetrahydropyranyl are preferred.
- heteroaryl (or "hetaryl”) stands for an aromatic heterocyclic radical.
- heterocycle structures shown in the present application only one bond to the neighboring group is indicated, for example in the heterocycle structures which are suitable for Y, the bond to the unit Q. Independently of this, however, these heterocycle structures can carry further substituents as indicated.
- the present invention further relates to a process for the preparation of the compounds of the formula (I), characterized in that
- E either represents a leaving group which is substituted in the presence of a base or is an optionally activated hydroxy function
- E either represents a leaving group which is substituted in the presence of a base or is an optionally activated hydroxy function
- E either represents a leaving group which is substituted in the presence of a base or is an optionally activated hydroxy function
- Va stands for O or S
- E either represents a leaving group which is substituted in the presence of a base or is an optionally activated hydroxy function:
- R ⁇ and R 2 b each independently represent CN or COO Alk, where Alk represents a straight-chain or branched alkyl radical having up to 6 carbon atoms,
- M represents an aryl or heteroaryl radical, a straight-chain or branched alkyl, alkenyl or alkynyl radical or cycloalkyl radical or an arylalkyl, an arylalkenyl or an arylalkynyl radical,
- the compounds of the formula (I) can also be prepared on a solid phase, such as a polystyrene resin, particularly preferably a commercially available Wang polystyrene resin.
- the resin is initially dissolved in a swollen like dimethylformamide (DMF).
- the corresponding carboxylic acid serving as the starting compound is then bound to the resin by standard methods.
- the carboxylic acid can be bound to the resin in the presence of a base such as pyridine or 4-dimethylaminopyridine (DMAP) and a reagent which activates the carboxyl unit, such as an acid halide, for example dichlorobenzoyl chloride, in a solvent such as dimethylformamide (DMF).
- a base such as pyridine or 4-dimethylaminopyridine (DMAP)
- DMAP 4-dimethylaminopyridine
- a reagent which activates the carboxyl unit such as an acid halide, for example dichlorobenzoyl chloride
- reaction mixture is left to stir for at least 2 hours, preferably 12 hours, particularly preferably about 24 hours, at room temperature and normal pressure, the carboxylic acid being used in excess, preferably in a two to three-fold excess, with respect to the loading of the solid phase.
- the carboxylic acid bound to the resin can be derivatized without having to be separated from the resin beforehand.
- a corresponding 4-aminobenzoic acid or 4-formylbenzoic acid derivative can be attached to the resin, then via successive reductive amination reactions, as described below for the preparation of the compounds of the formula (II), (IV) and (VI) a compound of the formula (VUI) are reacted, which can then be converted into the target compounds on the solid phase analogously to process [D].
- the resin is split off after the desired structure of the target compound on the solid phase in a conventional manner in an acidic environment.
- the product separated from the resin can, after removal of any solvents which may be present, be purified by known purification processes, such as, for example, chromatographic processes.
- purification processes such as, for example, chromatographic processes.
- Preferred solvents for the processes according to the invention are conventional organic solvents which do not change under the reaction conditions or water.
- ethers such as diethyl ether, butyl methyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, or hydrocarbons such as benzene, toluene, xylene or petroleum ether, or amides such as dimethylformamide or hexamethylphosphorium triamide, or 1,3-dimethyl-2-imidazole are preferably used for the process according to the invention -on, 1, 3-dimethyl-tetrahydro- pyrimidin-2-one, acetonitrile, ethyl acetate or dimethyl sulfoxide can be used. It is of course also possible to use mixtures of the abovementioned solvents.
- the bases preferred for the processes according to the invention comprise basic compounds conventionally used for basic reactions.
- Alkali metal hydrides such as sodium hydride or potassium hydride, or alkali metal alcoholates such as sodium methoxide, sodium ethanolate, potassium methoxide, potassium ethanolate or potassium t-butoxide, or carbonates such as sodium carbonate, cesium carbonate or potassium carbonate or amides such as sodium amide or lithium diisopropylamide, or organolith such as phenyllithium, butyllithium or methyl lithium or sodium hexamethyldisilazane can be used.
- Processes A to C according to the invention can preferably be carried out in acetonitrile in each case by reaction of the compounds (II) and (UT), (TV) and (V) or (VI) and (VII) in the presence of a base such as sodium carbonate, Et 3 N, DABCO , K 2 CO 3 , KOH, NaOH or NaH can be carried out.
- the reaction can generally be carried out in a temperature range from -20 ° C. to + 90 ° C., preferably from 0 ° C. to + 70 ° C.
- the reaction can be carried out at normal pressure, elevated or reduced pressure (for example in a range from 0.5 to 5 bar). In general, the reaction is carried out at normal pressure.
- the reaction can generally be carried out in a temperature range from -20 ° C. to + 90 ° C., preferably from 0 ° C. to + 90 ° C.
- the reaction can be carried out at normal pressure, elevated or reduced pressure (for example in a range from 0.5 to 5 bar). In general, the reaction is carried out at normal pressure.
- a compound of the formula (I) is prepared by nucleophilic substitution of a leaving group E in the compound of the formula (LX) by the hydroxyl or thiol function of the compound of the formula (Vi ⁇ ).
- the following leaving groups E are, for example: halogen, tosylate, mesylate, or a hydroxyl function activated by reagents such as diisopropylazodicarboxylate / PPh 3 (Mitsonobu reaction).
- a compound of the formula (I) is reacted by reacting a compound of the formula (XI) which contains a substitutable group L with a compound of the group (XII) in the presence of a palladium compound and, if appropriate, a reducing agent and other additives represented in basic medium.
- the reaction formally represents a reductive coupling of the compounds of the formulas (XI) and (XII), as described, for example, in LS Hegedus, Organometallics in Synthesis, M. Schlosser, Ed., Wiley & Sons, 1994.
- substitutable group L in the compounds of the formula (XI) for example a halogen radical such as Br or I or a conventional leaving group such as a triflate radical can be used.
- a palladium (II) compound such as Cl 2 Pd (PPh 3 ) 2 or Pd (OAc) 2 or a palladium (O) compound such as Pd (PPh 3 ) 4 or Pd 2 (dba) 3 can be used as the palladium compound become.
- a reducing agent such as triphenylphosphine or other additives such as Cu (I) Br, NBu 4 NCl, LiCl or Ag 3 PO 4 can also be added to the reaction mixture (cf. T Jeffery, Tetrahedron lett. 1985, 26, 2667-2670; T. Jeffery, J. Chem. Soc, Chem. Commun. 1984, 1287-1289; S. Bräse, A. deMejiere in "Metal-catalyzed cross-coupling reactions", Ed. F. Diederich, PJ Stang , Wiley-VCH,
- the reaction is carried out in the presence of a conventional base such as Na 2 CO 3 , NaOH or triethylamine.
- Suitable solvents are the organic solvents mentioned above, ethers such as dimethoxyethane being particularly preferred.
- the reaction can generally be in one Temperature range from -20 ° C to + 90 ° C, preferably from 0 ° C to + 90 ° C.
- the reaction can be carried out at normal pressure, elevated or reduced pressure (for example in a range from 0.5 to 5 bar). In general, the reaction is carried out at normal pressure.
- the first step of process G thus proceeds analogously to process D, with compounds of the formula (XIH) being reacted with the alcohols or thiols of the formula (XIII) here instead of the compounds of the formula (IX).
- the unsaturated compounds of the formula (XIV) are thus obtained, which can be converted into the compounds of the formula (I) by conventional hydrogenation processes.
- Process G can be carried out in one of the above-mentioned organic solvents. Ethyl acetate is preferred.
- the reaction can generally be carried out in a temperature range from -20 ° C. to + 90 ° C., preferably from 0 ° C. to + 90 ° C.
- the reaction can be carried out at normal pressure, elevated or reduced pressure (for example in a range from 0.5 to 5 bar). In general, the reaction is carried out at normal pressure.
- the new compounds of the formula II, IV and VI can be obtained in a generally known manner by the following methods: by reaction of amines of the formulas (XV), (XVI) and (XV ⁇ )
- radicals R 2 , R 3 , m, V, Q, U, W, X, Y and A have the meanings given above;
- Ua, Wa and Xa have the meaning of U, W and X, but are shortened by one carbon unit, and
- T represents hydrogen or a -CC alkyl function, which can also be linked to Ua or Xa to form a cycle, and the other radicals are as defined above,
- Va O or S
- the other residues are as defined above.
- (Ilb) is obtained, for example, by first reacting (XVa) with (XVIII) to form a Schiff base and then reducing it with common reducing agents, such as NaBH, H 2 / Pd / C etc., or directly under the conditions of a reductive one
- a compound of formula (XXIII) can be obtained from the compound of formula (IIc) thus obtained by protecting the amino function (see also T.W. Greene, P.G.M.
- an N-protecting group as in (XXII) can be introduced and removed using standard methods (cf. TW Greene, PGM Wuts, Protective Groups in Organic Synthesis, second edition, New York, 1991).
- the protective group can be introduced by reacting the amine with tert-butyl pyrrocarbonate in polar or non-polar solvents at 0 ° C to 25 ° C.
- the protecting group can be split off to (Ila) using numerous acids, such as, for example, HC1, H 2 SO 4 or CF 3 COOH, at from 0 ° to 25 ° C. (cf. literature cited above).
- 4-chloromethylbiphenyl compounds which carry a further substituent in the 4'-position can be obtained by coupling 4- (B (OH) 2 - Ph-CHO with the corresponding bromophenyl compounds substituted in the 4-position in the presence of palladium catalysts, such as for example Pd (PPh 3 ) or PdCl 2 (PPh3) 2 and sodium carbonate to the corresponding biphenyl Compounds and subsequent reduction to alcohol with NaBH 4 and conversion to the corresponding chloride with SOCl 2 are prepared.
- palladium catalysts such as for example Pd (PPh 3 ) or PdCl 2 (PPh3) 2
- the compounds can also be prepared by generally known methods, e.g. by reacting an alcohol with a chlorination reagent, e.g. Thionyl chloride or sulfuryl chloride can be produced (see e.g. J. March, Advanced Organic Chemistry, fourth edition, Wiley, 1992, page 1274 or the literature cited therein).
- a chlorination reagent e.g. Thionyl chloride or sulfuryl chloride
- Amines of the formula (XV) are commercially available, known from the literature, or can be synthesized analogously to processes known from the literature (cf., for example, Tetrahedron 1997, 53, 2075; J. Med. Chem. 1984, 27, 1321; WO97 / 29079; J. Org. Chem. 1982, 47, 5396).
- these compounds can be selected from the corresponding halide compounds and in particular chloride compounds in which a W'-Hal group is used instead of the W-NH 2 radicals of the compounds of the formula (XV), where W 'is a radical W shortened by one C atom, by substitution of the halide residue by a cyano group to obtain the corresponding nitrile compounds and reduction of the nitrile group or by reaction of corresponding aldehyde compounds in which instead of the residues W-NH 2 of the compounds of the formula (XV) there is a group W'-CHO, where W represents a radical W shortened by one carbon atom, can be obtained with nitromethane and subsequent reduction.
- W'-Hal group is used instead of the W-NH 2 radicals of the compounds of the formula (XV)
- a few exemplary synthetic routes for the amines of the formula (XV) are listed below, the reagents indicated generally representing only one of several possibilities.
- a reduction reaction from aldehyde to alcohol groups, substitution of alcohol groups by halogen groups, substitution of halogen functions by nitrile groups, or reductions of nitrile groups to corresponding amino groups can be carried out with all reactants conventionally used for such reactions (cf. e.g. the corresponding chapter in March, Advanced Organic Chemistry, Wiley, 3 , ed., 1985).
- the radicals given have the same meaning as defined above.
- the corresponding hydroxycarboxylic acids or hydroxycarnonic esters can also be used instead of the hydroxyaldehydes become.
- the conversion of the primary hydroxyl group into the nitrile group can also be carried out via the corresponding bromide, mesylate, tosylate or acetate instead of via the corresponding halide.
- This process can be used, for example, starting from 2-hydroxynaphth-1-aldehyde, 1-hydroxymethyl-2-methoxynaphthalene or one of the following commercially available or literature-known hydroxyaldehydes:
- the 2-cyanomethyl-3-hydroxypyridine is also according to Desideri et al, J. Heterocycl.
- Amines of the formula (XVI) are commercially available, known from the literature, or can be synthesized analogously to processes known from the literature (cf., for example, J. Am. Chem. Soc. 1982, 104, 6801; Chem. Lett. 1984, 1733; J. Med Chem. 1998, 41, 5219; DE-2059922).
- Amines of the formula (XVII) are commercially available, known from the literature, or can be synthesized analogously to processes known from the literature (see, for example, J. Org. Chem. 1968, 33, 1581; Bull. Chem. Soc. Jpn. 1973, 46, 968 ; J. Am. Chem. Soc. 1958, 80, 1510; J. Org. Chem. 1961, 26, 2507; Synth. Commun. 1989, 19, 1787).
- Amines of the formulas (XV), (XVI) and (XVII) can also be according to generally known
- Carbonyl compounds of the formula (XVIII) are commercially available, known from the literature, or can be synthesized analogously to processes known from the literature (see e.g. J. Med. Chem. 1989, 32, 1277; Chem. Ber. 1938, 71, 335; Bull. Soc. Chim. Fr. 1996, 123, 679).
- Carbonyl compounds of the formula (XIX) are commercially available, known from the literature, or can be synthesized in analogy to processes known from the literature,
- Carbonyl compounds of the formula (XX) are commercially available, known from the literature, or can be synthesized analogously to processes known from the literature
- Carbonyl compounds of the formulas (XVIII), (XIX) and (XX) can also be prepared by generally known methods, e.g. by oxidation of alcohols, the reduction of acid chlorides, or the reduction of nitriles (see e.g. J.
- the compounds according to the invention show an unforeseeable, valuable spectrum of pharmacological activity.
- the compounds according to the invention in particular the compounds of the general formula (I), lead to vascular relaxation, platelet aggregation inhibition and to a reduction in blood pressure and to an increase in the coronary blood flow. These effects are mediated by direct stimulation of soluble guanylate cyclase and an intracellular increase in cGMP.
- cardiovascular diseases such as, for example, for the treatment of high blood pressure and heart failure, stable and unstable angina pectoris, peripheral and cardiac vascular diseases, of arrhythmias, for the treatment of thromboembolic diseases and ischemia such as myocardial infarction, stroke, transistoric and Ischemic attacks, peripheral circulatory disorders, prevention of restenoses such as after thrombolysis therapies, percutaneous transluminal angioplasties (PTA), percutaneous transluminal coronary angioplasties (PTCA), bypass and for the treatment of arteriosclerosis, fibrotic diseases such as liver fibrosis and diseases of the pulmonary fibrosis or pulmonary fibrosis system, for example, of the uterine fibrosis or pulmonary fibrosis system, for example, of the asthma or pulmonary fibrosis system Prostate hypertrophy, erectile dysfunction, female sexual dysfunction and incontinence as well as for the treatment of glaucoma.
- thromboembolic diseases and ischemia such as myocardial infar
- the compounds described in the present invention are also active compounds for combating diseases in the central nervous system which are characterized by disorders of the NO / cGMP system.
- they are suitable for eliminating cognitive deficits, for improving learning and memory and for treating Alzheimer's disease.
- They are also suitable for the treatment of diseases of the central nervous system such as anxiety, tension and depression, central nervous system-related sexual dysfunctions and sleep disorders, as well as for the regulation of pathological disorders in the intake of food, beverages and addictive substances.
- the active ingredients are also suitable for regulating cerebral blood flow and are therefore effective means of combating migraines.
- the compounds according to the invention in particular the compounds of the general formula (I), can likewise be used to combat painful conditions.
- the compounds according to the invention have anti-inflammatory activity and can therefore be used as anti-inflammatory agents.
- Rabbits are anesthetized or killed by intravenous injection of thiopental sodium (approx. 50 mg / kg,) and exsanguinated.
- the saphenous artery is removed and divided into 3 mm wide rings.
- the rings are individually mounted on a triangular pair of hooks made of 0.3 mm special wire (Remanium®) that is open at the end.
- Each ring is placed in 5 ml organ baths with 37 ° C warm, carbogen-gassed Krebs-Henseleit solution of the following composition (mM): NaCl: 119; KC1: 4.8; CaCl 2 x 2 H 2 O: 1; MgSO 4 x 7 H 2 O: 1.4; KH 2 PO 4 : 1.2; NaHCO3: 25; Glucose: 10; Bovine serum albumin: 0.001%.
- the contraction force is recorded with Statham UC2 cells, amplified and digitized via A / D converter (DAS-1802 HC, Keithley Instruments Munich), and recorded in parallel on line recorders. Contractions are induced by adding phenylephrine.
- the substance to be examined is added in increasing doses in each further run and the level of the contraction achieved under the influence of the test substance is compared with the level of the contraction achieved in the last previous run. From this, the concentration is calculated, which is necessary to achieve the contraction achieved in the pre-control Reduce 50% (IC 50 ).
- the standard application volume is 5 ⁇ l.
- the DMSO proportion in the bath solution corresponds to 0.1%.
- Stasch Purified soluble guanylyl cyclase expressed in a baculovirus / Sf9 System: Stimulation by YC-1, nitric oxide, and carbon oxide. J. Mol. Med. 77 (1999): 14-23.
- the heme-free guanylate cyclase was obtained by adding Tween 20 to the sample buffer (0.5% in the final concentration).
- the activation of the sGC by a test substance is given as n-fold stimulation of the basal activity.
- the present invention includes pharmaceutical preparations which, in addition to non-toxic, inert pharmaceutically suitable excipients, include the inventive
- the active ingredient can optionally also be present in microencapsulated form in one or more of the carriers mentioned above.
- the therapeutically active compounds in particular the compounds of the general formula (I), should be present in the pharmaceutical preparations listed above in a concentration of about 0.1 to 99.5, preferably about 0.5 to 95% by weight of the total mixture to be available.
- the pharmaceutical preparations listed above can also contain further active pharmaceutical ingredients.
- the active ingredient (s) according to the invention in total amounts of about 0.5 to about 500, preferably 5 to 100 mg / kg of body weight per 24 hours, optionally in the form multiple doses to achieve the desired results.
- a single dose contains the one or more according to the invention
- Active ingredients preferably in amounts of about 1 to about 80, in particular 3 to 30 mg / kg body weight.
- BABA n-butyl acetate / n-butanol / glacial acetic acid / phosphate buffer pH 6
- the mixture is heated to reflux for five hours. After cooling, it is acidified with dilute hydrochloric acid and briefly heated again (5 minutes). Then it is made alkaline with sodium hydroxide solution and extracted with ether. The organic extract is dried over anhydrous sodium sulfate. After filtering and spinning in, 14.2 g of a yellow waxy solid are obtained, which is only approx.
- the toluene is then removed on a tot evaporator and the residue is taken up in methanol.
- the methanolic solution is mixed with ice cooling with 2.34 g (61.77 mmol) of solid sodium borohydride. After stirring for 30 minutes at room temperature, the mixture is neutralized with 5% sodium dihydrogenphosphate solution, diluted with water and extracted with ether. The organic phase is over
- the crude product obtained is purified by column chromatography (dichloromethane / methanol acetic acid 100: 10: 1.5) and 325 mg (1.01 mmol, 10% yield) of a colorless oil are obtained.
- Solvent B 0.3g HC1 (30%) / ll water gradient: A / B 2/98 to 95/5 within 2.5 min
- UV detector DAD 208-400 nm
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Pyridine Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10110750A DE10110750A1 (de) | 2001-03-07 | 2001-03-07 | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE10110750 | 2001-03-07 | ||
PCT/EP2002/001891 WO2002070510A2 (fr) | 2001-03-07 | 2002-02-22 | Nouveaux derives d'acide aminodicarbonique presentant des proprietes pharmaceutiques |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1368335A2 true EP1368335A2 (fr) | 2003-12-10 |
Family
ID=7676478
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02701292A Withdrawn EP1368335A2 (fr) | 2001-03-07 | 2002-02-22 | Nouveaux derives d'acide aminodicarbonique presentant des proprietes pharmaceutiques |
Country Status (7)
Country | Link |
---|---|
US (2) | US20040082798A1 (fr) |
EP (1) | EP1368335A2 (fr) |
JP (1) | JP4535679B2 (fr) |
AU (1) | AU2002234645A1 (fr) |
CA (1) | CA2439756C (fr) |
DE (1) | DE10110750A1 (fr) |
WO (1) | WO2002070510A2 (fr) |
Families Citing this family (232)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
DE10109859A1 (de) * | 2001-03-01 | 2002-09-05 | Bayer Ag | Neuartige Aminodicarbonsäurederivate |
DE10110747A1 (de) * | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung |
DE10216145A1 (de) * | 2002-04-12 | 2003-10-23 | Bayer Ag | Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom |
WO2004108681A1 (fr) | 2003-06-06 | 2004-12-16 | Fibrogen, Inc. | Composes heteroaryliques contenant de l'azote et leur utilisation dans l'augmentation de l'erythropoietine endogene |
TWI372050B (en) * | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
US7276608B2 (en) * | 2003-07-11 | 2007-10-02 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
PL1651612T3 (pl) | 2003-07-22 | 2012-09-28 | Astex Therapeutics Ltd | Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3) |
US7696210B2 (en) | 2004-06-17 | 2010-04-13 | Wyeth | Gonadotropin releasing hormone receptor antagonists |
MXPA06014797A (es) | 2004-06-17 | 2007-02-16 | Wyeth Corp | Procesos para preparacion de antagonistas de receptor de hormona que libera gonadotropina. |
CA2810655C (fr) | 2004-06-24 | 2013-12-10 | Vertex Pharmaceuticals Incorporated | Modulateurs de transporteurs de cassette de liaison a l'atp |
US8354427B2 (en) * | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
US7868037B2 (en) | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
JP2008506702A (ja) | 2004-07-14 | 2008-03-06 | ピーティーシー セラピューティクス,インコーポレーテッド | C型肝炎を治療するための方法 |
US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
WO2006019832A1 (fr) | 2004-07-22 | 2006-02-23 | Ptc Therapeutics, Inc. | Thienopyridines utilisees pour traiter l'hepatite c |
DE102004042607A1 (de) * | 2004-09-03 | 2006-03-09 | Bayer Healthcare Ag | Substituierte Phenylaminothiazole und ihre Verwendung |
US20070225318A1 (en) * | 2004-09-20 | 2007-09-27 | Biolipox Ab | Pyrazole Compounds Useful In The Treatment Of Inflammation |
EP1814866A2 (fr) * | 2004-11-23 | 2007-08-08 | Wyeth a Corporation of the State of Delaware | Antagonistes du recepteur d'hormone de liberation de gonadotropine |
US7825256B2 (en) | 2004-12-01 | 2010-11-02 | Kalypsys, Inc. | Inducible nitric oxide synthase dimerization inhibitors |
US8110573B2 (en) | 2004-12-30 | 2012-02-07 | Astex Therapeutics Limited | Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases |
BRPI0606455A (pt) | 2005-01-21 | 2008-03-11 | Astex Therapeutics Ltd | compostos farmacêuticos |
MX2007008810A (es) | 2005-01-21 | 2007-11-21 | Astex Therapeutics Ltd | Compuestos farmaceuticos. |
US7538113B2 (en) | 2005-02-18 | 2009-05-26 | Wyeth | 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
US7534796B2 (en) | 2005-02-18 | 2009-05-19 | Wyeth | Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor |
US7582634B2 (en) | 2005-02-18 | 2009-09-01 | Wyeth | 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
US20060189619A1 (en) * | 2005-02-24 | 2006-08-24 | Wyeth | 3-({4-[2-(4-Tert-butylphenyl)-1h-benzimidazol-4-yl]piperazin-1-yl}methyl)pyrido[2,3-b]]pyrazi ne compounds |
US7531542B2 (en) | 2005-05-18 | 2009-05-12 | Wyeth | Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor |
US7582636B2 (en) | 2005-05-26 | 2009-09-01 | Wyeth | Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor |
US20060281768A1 (en) * | 2005-06-10 | 2006-12-14 | Gaul Michael D | Thienopyrimidine and thienopyridine kinase modulators |
TW200800911A (en) * | 2005-10-20 | 2008-01-01 | Biolipox Ab | Pyrazoles useful in the treatment of inflammation |
DE102005050497A1 (de) | 2005-10-21 | 2007-04-26 | Bayer Healthcare Ag | Difluorphenol-Derivate und ihre Verwendung |
DE102005050377A1 (de) * | 2005-10-21 | 2007-04-26 | Bayer Healthcare Ag | Heterocyclische Verbindungen und ihre Verwendung |
DE102005050376A1 (de) | 2005-10-21 | 2007-05-31 | Bayer Healthcare Ag | Dicarbonsäure-Derivate und ihre Verwendung |
DE102005050498A1 (de) | 2005-10-21 | 2007-06-06 | Bayer Healthcare Aktiengesellschaft | Cyclopropylessigsäure-Derivate und ihre Verwendung |
DE102005050375A1 (de) | 2005-10-21 | 2007-04-26 | Bayer Healthcare Ag | Tetrazol-Derivate und ihre Verwendung |
EP1943234A1 (fr) * | 2005-10-31 | 2008-07-16 | Biolipox AB | Utilisation de triazoles comme inhibiteurs de la lipoxygenase |
TW200732320A (en) * | 2005-10-31 | 2007-09-01 | Biolipox Ab | Pyrazoles useful in the treatment of inflammation |
WO2007052000A1 (fr) * | 2005-11-01 | 2007-05-10 | Biolipox Ab | Utilisation de pyrazoles dans le traitement de l'inflammation |
CN101374849A (zh) * | 2005-12-24 | 2009-02-25 | 沃泰克斯药物股份有限公司 | 作为abc转运蛋白调控剂的喹啉-4-酮衍生物 |
BRPI0620960A2 (pt) | 2005-12-28 | 2011-11-29 | Vertex Pharmaceuticals Incorporated | formas sólidas de n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-didro-4- oxiquinolina-3- carboxamida |
EP1968579A1 (fr) | 2005-12-30 | 2008-09-17 | Astex Therapeutics Limited | Composes pharmaceutiques |
EP2476669A1 (fr) | 2006-01-27 | 2012-07-18 | Fibrogen, Inc. | Composants de cyanoisoquinoline et procédés d'utilisation correspondants |
JP5111491B2 (ja) | 2006-04-04 | 2013-01-09 | フィブロジェン, インコーポレイテッド | ピロロ−およびピラゾロ−ピリミジン化合物、およびそれらの使用方法 |
DE102006024024A1 (de) | 2006-05-23 | 2007-11-29 | Bayer Healthcare Aktiengesellschaft | Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung |
EP2043635A2 (fr) * | 2006-06-29 | 2009-04-08 | Astex Therapeutics Limited | Combinaisons pharmaceutiques |
JP5523829B2 (ja) | 2006-06-29 | 2014-06-18 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
ES2376771T3 (es) * | 2006-08-21 | 2012-03-16 | Genentech, Inc. | Compuestos aza-benzofuranilo y métodos de utilización |
AU2007286807B2 (en) * | 2006-08-21 | 2013-03-21 | Genentech, Inc. | Aza-benzothiophenyl compounds and methods of use |
DE102006042143A1 (de) * | 2006-09-08 | 2008-03-27 | Bayer Healthcare Aktiengesellschaft | Neue substituierte Bipyridin-Derivate und ihre Verwendung |
DE102006044696A1 (de) | 2006-09-22 | 2008-03-27 | Bayer Healthcare Ag | 3-Cyano-5-thiazaheteroaryl-dihydropyridine und ihre Verwendung |
DE102006056739A1 (de) * | 2006-12-01 | 2008-06-05 | Bayer Healthcare Ag | Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung |
DE102006056740A1 (de) * | 2006-12-01 | 2008-06-05 | Bayer Healthcare Ag | Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung |
DE102007009494A1 (de) | 2007-02-27 | 2008-08-28 | Bayer Healthcare Ag | Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung |
DE102007015035A1 (de) | 2007-03-29 | 2008-10-02 | Bayer Healthcare Ag | Substituierte Dibenzoesäure-Derivate und ihre Verwendung |
DE102007015034A1 (de) | 2007-03-29 | 2008-10-02 | Bayer Healthcare Ag | Lactam-substituierte Dicarbonsäuren und ihre Verwendung |
DE102007019691A1 (de) | 2007-04-26 | 2008-10-30 | Bayer Healthcare Ag | Verwendung von acyclisch substituierten Furopyrimidin-Derivaten zur Behandlung der pulmonalen arteriellen Hypertonie |
DE102007019690A1 (de) | 2007-04-26 | 2008-10-30 | Bayer Healthcare Ag | Verwendung von cyclisch substituierten Furopyrimidin-Derivaten zur Behandlung der pulmonalen arteriellen Hypertonie |
DE102007026392A1 (de) | 2007-06-06 | 2008-12-11 | Bayer Healthcare Ag | Lösungen für die Perfusion und Konservierung von Organen und Geweben |
DE102007027799A1 (de) | 2007-06-16 | 2008-12-18 | Bayer Healthcare Ag | Substituierte Furopyrimidine und ihre Verwendung |
DE102007027800A1 (de) | 2007-06-16 | 2008-12-18 | Bayer Healthcare Ag | Substituierte bicyclische Heteroaryl-Verbindungen und ihre Verwendung |
MX2009013952A (es) | 2007-06-28 | 2010-01-28 | Novartis Ag | Moduladores de calicreina 7. |
DE102007035367A1 (de) | 2007-07-27 | 2009-01-29 | Bayer Healthcare Ag | Substituierte Aryloxazole und ihre Verwendung |
DE102007036076A1 (de) | 2007-08-01 | 2009-02-05 | Bayer Healthcare Aktiengesellschaft | Dipeptoid-Produgs und ihre Verwendung |
DE102007042754A1 (de) | 2007-09-07 | 2009-03-12 | Bayer Healthcare Ag | Substituierte 6-Phenylnikotinsäuren und ihre Verwendung |
DE102007051762A1 (de) | 2007-10-30 | 2009-05-07 | Bayer Healthcare Ag | Substituierte Pyrrolotriazine und ihre Verwendung |
DE102007054786A1 (de) | 2007-11-16 | 2009-05-20 | Bayer Healthcare Ag | Trisubstituierte Furopyrimidine und ihre Verwendung |
DE102007061756A1 (de) | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Substituierte 4-Aminopyrimidin-5-carbonsäuren und ihre Verwendung |
DE102007061757A1 (de) | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Substituierte 2-Phenylpyrimidin-5-carbonsäuren und ihre Verwendung |
DE102007061764A1 (de) | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Anellierte Cyanopyridine und ihre Verwendung |
DE102007061763A1 (de) * | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Substituierte azabicyclische Verbindungen und ihre Verwendung |
DE102007061766A1 (de) | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | 4-(4-Cyano-2-thioaryl)-dihydropyrimidinone und ihre Verwendung |
DE102008052013A1 (de) | 2008-10-17 | 2010-04-22 | Bayer Schering Pharma Aktiengesellschaft | 4-(4-Cyano-2-thioaryl)-dihydropyrimidinone und ihre Verwendung |
DE102008022521A1 (de) | 2008-05-07 | 2009-11-12 | Bayer Schering Pharma Aktiengesellschaft | 1,4-Diaryl-pyrimidopyridazin-2,5-dione und ihre Verwendung |
DE102008007400A1 (de) | 2008-02-04 | 2009-08-06 | Bayer Healthcare Ag | Substituierte Furane und ihre Verwendung |
DE102008013587A1 (de) | 2008-03-11 | 2009-09-17 | Bayer Schering Pharma Aktiengesellschaft | Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung |
JP5432890B2 (ja) * | 2008-04-04 | 2014-03-05 | 武田薬品工業株式会社 | 複素環誘導体及びその用途 |
WO2009143992A1 (fr) * | 2008-05-29 | 2009-12-03 | Bayer Schering Pharma Aktiengesellschaft | Dicyanopyridines substituées par du 2-alcoxy et leur utilisation |
DE102008030207A1 (de) | 2008-06-25 | 2009-12-31 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 7-Sulfanylmethyl-, 7-Sulfinylmethyl- und 7-Sulfonylmethyl-Indole und ihre Verwendung |
DE102008030206A1 (de) | 2008-06-25 | 2009-12-31 | Bayer Schering Pharma Aktiengesellschaft | 3-Cyanoalky- und 3-Hydroxyalkyl-Indole und ihre Verwendung |
AR072297A1 (es) * | 2008-06-27 | 2010-08-18 | Novartis Ag | Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona. |
DE102008039083A1 (de) | 2008-08-21 | 2010-02-25 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Aminopyrazole und ihre Verwendung |
DE102008039082A1 (de) | 2008-08-21 | 2010-02-25 | Bayer Schering Pharma Aktiengesellschaft | Azabicyclisch-substituierte 5-Aminopyrazole und ihre Verwendung |
DE102008054205A1 (de) | 2008-10-31 | 2010-05-06 | Bayer Schering Pharma Aktiengesellschaft | Verwendung von Helium-Sauerstoff-Gasgemischen zur Behandlung der pulmonalen arteriellen Hypertonie |
JP5649584B2 (ja) | 2008-11-14 | 2015-01-07 | フィブロジェン インコーポレイテッド | Hifヒドロキシラーゼ阻害剤としてのチオクロメン誘導体 |
DE102008060967A1 (de) | 2008-12-06 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Phenylsulfonyltriazolone und ihre Verwendung |
DE102008062566A1 (de) | 2008-12-16 | 2010-06-17 | Bayer Schering Pharma Aktiengesellschaft | Aminosäureester-Prodrugs und ihre Verwendung |
DE102008062567A1 (de) | 2008-12-16 | 2010-06-17 | Bayer Schering Pharma Aktiengesellschaft | Dipeptoid-Prodrugs und ihre Verwendung |
DE102009004197A1 (de) | 2009-01-09 | 2010-07-15 | Bayer Schering Pharma Aktiengesellschaft | Heterocyclisch anellierte Diaryldihydropyrimidin-Derivate und ihre Verwendung |
DE102009006602A1 (de) | 2009-01-29 | 2010-08-05 | Bayer Schering Pharma Aktiengesellschaft | Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs |
DE102010001064A1 (de) | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
DE102009013642A1 (de) | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Phenylalaninderivate und deren Verwendung |
US8476442B2 (en) | 2009-03-20 | 2013-07-02 | Vertex Pharmaceutical Incorporated | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
DE102009016553A1 (de) | 2009-04-06 | 2010-10-07 | Bayer Schering Pharma Aktiengesellschaft | Sulfonamid- und Sulfoximin-substituierte Diaryldihydropyrimidinone und ihre Verwendung |
DE102009028929A1 (de) | 2009-08-27 | 2011-07-07 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Heterocyclisch-substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
EP2539326B1 (fr) | 2010-02-27 | 2017-05-03 | Bayer Intellectual Property GmbH | Aryltriazolone liée à un bis-aryle et son utilisation |
DE102010020553A1 (de) | 2010-05-14 | 2011-11-17 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 8-Alkoxy-2-aminotetralin-Derivate und ihre Verwendung |
CN103038232B (zh) | 2010-05-26 | 2016-01-20 | 阿德弗里奥药品有限责任公司 | 单独的和与PDE5抑制剂相组合的sGC刺激剂、sGC活化剂用于治疗系统性硬化症(SSc)的用途 |
DE102010030187A1 (de) | 2010-06-16 | 2011-12-22 | Bayer Schering Pharma Aktiengesellschaft | 4-Cyan-2-sulfonylphenyl)pyrazolyl-substituierte Pyridinone und Pyrazinone und ihre Verwendung |
EP2687210A1 (fr) | 2010-06-25 | 2014-01-22 | Bayer Intellectual Property GmbH | Stimulateurs et activateurs de la guanylate cyclase soluble pour leur utilisation dans le traitement de la drépanocytose et de la conservation des substituts sanguins |
DE102010030688A1 (de) | 2010-06-30 | 2012-01-05 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Dicyanopyridine und ihre Verwendung |
HUE031710T2 (en) | 2010-07-14 | 2017-07-28 | Novartis Ag | IP receptor agonist heterocyclic compounds |
DE102010040187A1 (de) | 2010-09-02 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Substituierte N-Phenethyl-triazolonacetamide und ihre Verwendung |
US20120058983A1 (en) | 2010-09-02 | 2012-03-08 | Bayer Pharma Aktiengesellschaft | Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension |
DE102010040924A1 (de) | 2010-09-16 | 2012-03-22 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Phenylacet- und Phenylpropanamide und ihre Verwendung |
US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
AR087020A1 (es) | 2011-07-01 | 2014-02-05 | Bayer Ip Gmbh | Polipeptidos de fusion de relaxina y usos de los mismos |
JP2014529293A (ja) | 2011-07-08 | 2014-11-06 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | レラキシンを放出する融合タンパク質およびその使用 |
US8883819B2 (en) | 2011-09-01 | 2014-11-11 | Irm Llc | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
WO2013105061A1 (fr) | 2012-01-13 | 2013-07-18 | Novartis Ag | Dihydropyrido [2,3-b]pyrazines fusionnées comme agonistes des récepteurs ip pour le traitement de l'hypertension artérielle pulmonaire (hap) et des troubles connexes |
WO2013105057A1 (fr) | 2012-01-13 | 2013-07-18 | Novartis Ag | Pyrroles fondus utilisés comme agonistes du récepteur ip pour le traitement de l'hypertension artérielle pulmonaire (htap) et des troubles associés |
WO2013105058A1 (fr) | 2012-01-13 | 2013-07-18 | Novartis Ag | 7,8-dihydropyrido[3,4-b]pyrazines utilisées comme agonistes du récepteur ip pour le traitement de l'hypertension artérielle pulmonaire (htap) et des troubles associés |
WO2013105066A1 (fr) | 2012-01-13 | 2013-07-18 | Novartis Ag | Sels d'un agoniste du récepteur ip |
US9115129B2 (en) | 2012-01-13 | 2015-08-25 | Novartis Ag | Substituted pyrido[2,3-B]pyrazines as IP receptor agonists |
US20150005311A1 (en) | 2012-01-13 | 2015-01-01 | Novartis Ag | IP receptor agonist heterocyclic compounds |
MX2014010253A (es) | 2012-02-27 | 2014-11-12 | Vertex Pharma | Composicion farmaceutica y administraciones de la misma. |
CN104470899B (zh) | 2012-03-09 | 2017-12-26 | 菲布罗根有限公司 | 作为hif羟化酶抑制剂的4‑羟基‑异喹啉化合物 |
WO2013144191A1 (fr) | 2012-03-29 | 2013-10-03 | Bayer Intellectual Property Gmbh | 2-amino-3-cyanopyridines substituées utilisées comme inhibiteurs de l'échange sodium-calcium et leurs utilisations dans le cas de maladies cardiovasculaires |
UA112897C2 (uk) | 2012-05-09 | 2016-11-10 | Байєр Фарма Акцієнгезелльшафт | Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань |
US8883823B2 (en) | 2012-07-16 | 2014-11-11 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
PL3470397T3 (pl) | 2012-07-16 | 2022-06-20 | Fibrogen, Inc. | Postacie krystaliczne inhibitora hydroksylazy prolilowej |
EP3219706A1 (fr) | 2012-07-16 | 2017-09-20 | Fibrogen, Inc. | Procédé de fabrication de composés d'isoquinoline |
SI2875003T1 (sl) * | 2012-07-20 | 2017-03-31 | Bayer Pharma Aktiengesellschaft | Nove 5-aminotetrahidrokinolin-2-karboksilne kisline in njihova uporaba |
US9387203B2 (en) | 2012-07-20 | 2016-07-12 | Bayer Pharma Aktiengesellschaft | Substituted aminoindane- and aminotetralinecarboxylic acids and the use thereof |
ES2694297T3 (es) | 2013-01-24 | 2018-12-19 | Fibrogen, Inc. | Formas cristalinas de ácido {[1-ciano-5-(4-clorofenoxi)-4-hidroxi-isoquinolina-3-carbonilo]-amino}-acético |
EP2956455B1 (fr) | 2013-02-13 | 2017-05-17 | Novartis AG | Composes heterocycliques a activite agoniste sur le recepteur ip |
US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
WO2015011086A1 (fr) | 2013-07-25 | 2015-01-29 | Bayer Pharma Aktiengesellschaft | Stimulateurs de sgc ou activateurs de sgc et inhibiteurs de pde5 en combinaison avec un autre traitement pour la thérapie de la fibrose kystique |
UY35735A (es) | 2013-09-16 | 2015-04-30 | Bayer Pharma AG | Trifluorometilpirimidinonas disustituidas y su uso |
JP2016532721A (ja) | 2013-10-07 | 2016-10-20 | バイエル ファーマ アクチエンゲゼルシャフト | 環状チエノウラシルカルボキサミドおよびその使用 |
CA2927420A1 (fr) * | 2013-10-15 | 2015-04-23 | Toa Eiyo Ltd. | Derive d'acide 4-aminomethylbenzoique |
CN105873919A (zh) | 2013-11-08 | 2016-08-17 | 拜耳医药股份有限公司 | 作为类糜蛋白酶抑制剂的取代的尿嘧啶 |
EP3066098A1 (fr) | 2013-11-08 | 2016-09-14 | Bayer Pharma Aktiengesellschaft | Uraciles substitués et leur utilisation |
JP2017501164A (ja) | 2013-12-19 | 2017-01-12 | バイエル ファーマ アクチエンゲゼルシャフト | 置換されたピペリジニルテトラヒドロキノリン類 |
US20160318866A1 (en) | 2013-12-19 | 2016-11-03 | Bayer Pharma Aktiengesellschaft | Substituted bipiperidinyl derivatives |
JP2017503778A (ja) | 2013-12-19 | 2017-02-02 | バイエル ファーマ アクチエンゲゼルシャフト | アドレナリン受容体α2C拮抗薬としての置換されたビピペリジニル誘導体 |
JOP20200052A1 (ar) | 2013-12-19 | 2017-06-16 | Bayer Pharma AG | بيبريدينيل تتراهيدرو كوينولينات مستبدلة واستخدامها كمعضدات مستقبل أدريني ألفا- 2c |
WO2015150350A1 (fr) | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | Acides cyclopentanecarboxyliques à disubstitution 2,5 pour traiter des maladies des voies respiratoires |
CA2944617A1 (fr) | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | Derives chiraux d'acide cyclopentanecarboxylique a disubstitution 2,5 et leur utilisation |
WO2015150363A1 (fr) | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | Acides cyclopentanecarboxyliques à disubstitution 2,5 et leur utilisation |
US10112926B2 (en) | 2014-04-24 | 2018-10-30 | Novartis Ag | Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors |
WO2015162459A1 (fr) | 2014-04-24 | 2015-10-29 | Novartis Ag | Dérivés aminés de pyrazine utilisables en tant qu'inhibiteurs de la phosphatidylinositol 3-kinase |
KR20160141856A (ko) | 2014-04-24 | 2016-12-09 | 노파르티스 아게 | 포스파티딜이노시톨 3-키나제 억제제로서의 피라진 유도체 |
TW201625601A (zh) | 2014-07-02 | 2016-07-16 | 諾華公司 | 噻吩-2-基-吡啶-2-基-1h-吡唑-4-羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途 |
TW201625584A (zh) | 2014-07-02 | 2016-07-16 | 諾華公司 | 茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途 |
TW201625586A (zh) | 2014-07-02 | 2016-07-16 | 諾華公司 | 環己烯-1-基-吡啶-2-基-1h-吡唑-4-羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途 |
US10059707B2 (en) | 2014-08-01 | 2018-08-28 | Bayer Pharma AG | Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro- 1-6-naphthyridine-3-carbox-amide and the purification thereof for use as an active pharmaceutical ingredient |
WO2016037954A1 (fr) | 2014-09-09 | 2016-03-17 | Bayer Pharma Aktiengesellschaft | N,2-diarylquinoline-4-carboxamides substitués et utilisation desdits n,2-diarylquinoline-4-carboxamides substitués comme anti-inflammatoires |
WO2016046157A1 (fr) | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Dérivés de pyridobenzazépine et de pyridobenzazocine inhibant le facteur xia |
EP3204358B1 (fr) | 2014-10-07 | 2018-09-19 | Vertex Pharmaceuticals Incorporated | Co-cristaux de modulateurs du régulateur de conductance transmembranaire de la mucoviscidose |
EP3215498B1 (fr) | 2014-11-03 | 2018-08-22 | Bayer Pharma Aktiengesellschaft | Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées |
WO2016113205A1 (fr) | 2015-01-13 | 2016-07-21 | Bayer Pharma Aktiengesellschaft | Pentafluoréthylpyrimidinones substituées et leur utilisation |
UY36586A (es) | 2015-03-26 | 2016-10-31 | Bayer Pharma AG | Heterociclilmetiltienouracilos y uso de los mismos |
AU2016258847A1 (en) | 2015-05-06 | 2017-11-16 | Bayer Pharma Aktiengesellschaft | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of Digital Ulcers (DU) concomitant to Systemic Sclerosis (SSc) |
CN113712969A (zh) | 2015-07-23 | 2021-11-30 | 拜耳制药股份公司 | 可溶性鸟苷酸环化酶的刺激剂和/或活化剂及其用途 |
SI3337800T1 (sl) | 2015-08-21 | 2019-08-30 | Bayer Pharma Aktiengesellschaft, | Postopek priprave (4S)-4-(4-ciano-2-metoksifenil)-5-etoksi-2,8-dimetil-1,4-dihidro- 1-6-nafthiridin-3-karboksamida in njegovo čiščenje, za uporabo kot aktivna farmacevtska učinkovina |
WO2017081044A1 (fr) | 2015-11-13 | 2017-05-18 | Bayer Pharma Aktiengesellschaft | 4-(4-cyano-2-thioaryle)-dihydropyrimidinones destinées au traitement de plaies chroniques |
WO2017097671A1 (fr) | 2015-12-10 | 2017-06-15 | Bayer Pharma Aktiengesellschaft | Dérivés de perhydropyrrolo[3,4-c]pyrrole substitués et leur utilisation |
WO2017097792A1 (fr) | 2015-12-10 | 2017-06-15 | Bayer Pharma Aktiengesellschaft | Dérivés de 2-phényl-3-(pipérazinométhyl)imidazo[1,2-a]pyridine utilisés comme bloqueurs des canaux task-1 et task-2 pour traiter des troubles respiratoires liés au sommeil |
WO2017153235A1 (fr) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | N-cyclo-3-aryl-1-naphthamides substitués et leur utilisation |
WO2017153234A1 (fr) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | N-cyclo-2-arylchinolin-4-carboxamides substitués et leur utilisation |
WO2017153231A1 (fr) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | N-cyclo-2-arylisochinolinon-4-carboxamides substitués et leur utilisation |
TW201806943A (zh) | 2016-05-03 | 2018-03-01 | 拜耳製藥股份有限公司 | 經醯胺取代之苯基三唑衍生物及其用途 |
US10526314B2 (en) | 2016-05-03 | 2020-01-07 | Bayer Aktiengesellschaft | Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof |
US10525041B2 (en) | 2016-05-03 | 2020-01-07 | Bayer Pharma Aktiengesellschaft | Fluoroalkyl-substituted aryltriazole derivatives and uses thereof |
WO2017191105A1 (fr) | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | Dérivés d'aryltriazole à substitution amide et leurs utilisations |
WO2017191117A1 (fr) | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | Antagonistes du récepteur v1a destinés à une utilisation dans le traitement de maladies rénales |
US9988367B2 (en) | 2016-05-03 | 2018-06-05 | Bayer Pharma Aktiengesellschaft | Amide-substituted pyridinyltriazole derivatives and uses thereof |
US10800746B2 (en) | 2016-05-03 | 2020-10-13 | Bayer Pharma Aktiengesellschaft | Oxoalkyl-substituted phenyltriazole derivatives and uses thereof |
JOP20170113B1 (ar) | 2016-05-09 | 2023-03-28 | Bayer Pharma AG | مركبات 5، 6، 7، 8-رباعي هيدرو [1، 2، 4] تريازولو [4، 3-أ] بيريدين 3(2h)-ون مستبدلة ومركبات 2، 5، 6، 7-رباعي هيدرو-3h-بيرولو [2، 1-ج] [1، 2، 4] تريازول-3-ون واستخداماتها |
EP3481823B1 (fr) | 2016-07-11 | 2020-10-28 | Bayer Pharma Aktiengesellschaft | Amides de l'acide 1-pyridyl-naphthyridin-3-carboxylique substitués en position 7, et leur utilisation |
JOP20190005A1 (ar) | 2016-07-20 | 2019-01-20 | Bayer Ag | مركبات ديازاهيترو ثنائية الحلقة مستبدلة واستخداماتها |
WO2018041771A1 (fr) | 2016-09-02 | 2018-03-08 | Bayer Pharma Aktiengesellschaft | Thiéno-uraciles substitués par un groupe (1-méthylcyclopropyl)méthyle et leur utilisation |
EP3296298A1 (fr) | 2016-09-14 | 2018-03-21 | Bayer Pharma Aktiengesellschaft | 1-aryl-naphtyridin-3-ylcarboxamides substitués en position 7 et leur utilisation |
JOP20190045A1 (ar) | 2016-09-14 | 2019-03-14 | Bayer Ag | مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها. |
CA3037642A1 (fr) | 2016-09-23 | 2018-03-29 | Bayer Aktiengesellschaft | Thieno-uraciles a substitution n 3 -cyclique et leur utilisation |
JP7237823B2 (ja) | 2016-10-11 | 2023-03-13 | バイエル ファーマ アクチエンゲゼルシャフト | Sgcアクチベーターとミネラルコルチコイド受容体アンタゴニストとを含む組合せ |
JOP20190080A1 (ar) | 2016-10-14 | 2019-04-11 | Bayer Pharma AG | مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها |
US10927098B2 (en) | 2016-10-20 | 2021-02-23 | Bayer Pharma Aktiengesellschaft | Hydroxyalkyl-substituted triazole derivatives and uses thereof |
EP3338803A1 (fr) | 2016-12-21 | 2018-06-27 | Bayer Pharma Aktiengesellschaft | Formes pharmaceutiques comprenant des inhibiteurs de canaux de task-1 et task-3 et leur utilisation pour le traitement des troubles respiratoires |
EP3338764A1 (fr) | 2016-12-21 | 2018-06-27 | Bayer Pharma Aktiengesellschaft | Formes pharmaceutiques comprenant des inhibiteurs de canaux de task-1 et task-3 et leur utilisation pour le traitement des troubles respiratoires |
JOP20190148A1 (ar) | 2016-12-21 | 2019-06-18 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات قنوات task-1 و task-3 واستخدامها لمعالجة الاضطرابات التنفسية |
JOP20190141A1 (ar) | 2016-12-21 | 2019-06-12 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات لقناة task-1 و task-3 واستخدامها في معالجة اضطراب تنفسي |
AU2018219283B2 (en) | 2017-02-08 | 2022-05-19 | Bristol-Myers Squibb Company | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
BR112019021136A2 (pt) | 2017-04-10 | 2020-07-21 | Bayer Aktiengesellschaft | n-ariletil-2-arilquinolina-4-carboxamidas substituídas e uso das mesmas |
TWI770157B (zh) | 2017-04-10 | 2022-07-11 | 德商拜耳廠股份有限公司 | 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途 |
JOP20190284A1 (ar) | 2017-06-14 | 2019-12-11 | Bayer Pharma AG | مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس |
WO2018227427A1 (fr) | 2017-06-14 | 2018-12-20 | Bayer Aktiengesellschaft | Dérivés de diazépane pontés substitués et leur utilisation |
JP7065951B2 (ja) | 2017-09-22 | 2022-05-12 | ジュビラント エピパッド エルエルシー | Pad阻害剤としての複素環式化合物 |
CA3076476A1 (fr) | 2017-10-18 | 2019-04-25 | Jubilant Epipad LLC | Composes imidazo-pyridine a utiliser en tant qu'inhibiteurs de pad |
CR20200176A (es) | 2017-10-24 | 2020-07-24 | Bayer Pharma AG | Profármacos de derivados de triazol sustituido y sus usos |
US20210253557A1 (en) | 2017-10-24 | 2021-08-19 | Bayer Pharma Aktiengesellschaft | Substituted triazole derivatives and uses thereof |
WO2019081456A1 (fr) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | Utilisation d'activateurs et de stimulateurs de sgc comprenant une sous-unité bêta2 |
EP3700899A1 (fr) | 2017-10-24 | 2020-09-02 | Bayer Pharma Aktiengesellschaft | Dérivés de triazole substitués et utilisations associées |
WO2019081291A1 (fr) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | Promédicaments de dérivés de triazole substitués, et utilisations de ceux-ci |
WO2019081299A1 (fr) | 2017-10-24 | 2019-05-02 | Bayer Pharma Aktiengesellschaft | Dérivés de triazole substitués par une amine et utilisations associées |
WO2019081303A1 (fr) | 2017-10-24 | 2019-05-02 | Bayer Pharma Aktiengesellschaft | Dérivés de triazole substitués et utilisations associées |
EP3700900A1 (fr) | 2017-10-24 | 2020-09-02 | Bayer Aktiengesellschaft | Dérivés de triazole substitués et utilisations associées |
CA3080677A1 (fr) | 2017-11-06 | 2019-05-09 | Jubilant Prodel LLC | Derives de pyrimidine utilises en tant qu'inhibiteurs de l'activation de pd1/pd-l1 |
CA3081775A1 (fr) | 2017-11-07 | 2019-05-16 | Bayer Aktiengesellschaft | 2,4-dihydro-3h-1,2,4-triazol-3-ones substituees et leur utilisation |
MX2020005363A (es) | 2017-11-24 | 2020-10-01 | Jubilant Episcribe Llc | Compuestos heterociclicos como inhibidores de prmt5. |
EP3498298A1 (fr) | 2017-12-15 | 2019-06-19 | Bayer AG | Utilisation de stimulateurs sgc et d'activateurs sgc seuls ou en combinaison avec des inhibiteurs pde5 pour le traitement de troubles osseux, y compris l'ostéogénèse imparfaite (oi) |
MX2020009517A (es) | 2018-03-13 | 2021-01-20 | Jubilant Prodel LLC | Compuestos biciclicos como inhibidores de la interaccion/activacio n de pdl/pd-l1. |
EP3553082A1 (fr) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Anticorps greffés de peptide natriurétique du cerveau |
EP3553081A1 (fr) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Anticorps greffés de peptide natriurétique auriculaire |
EP3553079A1 (fr) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Anticorps greffés de peptide natriurétique de type c |
CA3098475A1 (fr) | 2018-04-30 | 2019-11-07 | Bayer Aktiengesellschaft | Utilisation d'activateurs de la gcs et de stimulateurs de la gcs pour le traitement de deficiences cognitives |
JOP20200287A1 (ar) | 2018-05-15 | 2020-11-09 | Bayer Ag | بنزاميدات مستبدلة بـ 3،1- ثيازول-2- يل للمعالجة من أمراض مصاحبة لتحسس الألياف العصبية |
BR112020021612A2 (pt) | 2018-05-17 | 2021-01-26 | Bayer Aktiengesellschaft | derivados substituídos de di-hidropirazolo pirazina carboxamida |
JP7457658B2 (ja) | 2018-05-22 | 2024-03-28 | ▲広▼▲東▼▲東▼▲陽▼光▲薬▼▲業▼有限公司 | フェニル置換ジヒドロナフチリジン化合物及びその使用 |
EP3574905A1 (fr) | 2018-05-30 | 2019-12-04 | Adverio Pharma GmbH | Procédé d'identification d'un sous-groupe de patients souffrant de dcssc qui bénéficie d'un traitement comportant des stimulateurs sgc et des activateurs sgc à un degré supérieur à celui d'un groupe de contrôle |
CA3120775A1 (fr) | 2018-11-27 | 2020-06-04 | Bayer Aktiengesellschaft | Procede de fabrication de formes pharmaceutiques contenant des inhibiteurs des canaux task-1 et task-3 et leur utilisation pour le traitement de troubles respiratoires |
US20220128561A1 (en) | 2019-01-17 | 2022-04-28 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble gyanylyl cyclase (sgc) |
WO2020164008A1 (fr) | 2019-02-13 | 2020-08-20 | Bayer Aktiengesellschaft | Procédé de préparation de microparticules poreuses |
WO2020165031A1 (fr) | 2019-02-15 | 2020-08-20 | Bayer Aktiengesellschaft | Dérivés isochinolin-pipéridinylméthanone substitués |
CN114793434A (zh) | 2019-10-18 | 2022-07-26 | 加利福尼亚大学董事会 | 作为用于治疗病原性血管病症的药剂的3-苯基磺酰基-喹啉衍生物 |
CN112707854B (zh) | 2019-10-25 | 2022-03-15 | 年衍药业(珠海)有限公司 | 吡咯酰胺类化合物及其用途 |
AR120404A1 (es) | 2019-11-06 | 2022-02-09 | Bayer Ag | CARBOXAMIDAS HETEROCÍCLICAS SUSTITUIDAS COMO ANTAGONISTAS DE LOS RECEPTORES a₂C ADRENÉRGICOS |
WO2021094208A1 (fr) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Antagonistes d'imidazo pyrimidine ep3 substitués |
WO2021094209A1 (fr) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Dérivés de pyrrolo triazine carboxamide substitués en tant qu'antagonistes du récepteur de la prostaglandine ep3 |
WO2021094210A1 (fr) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Dérivés de pyrazine carboxamide substitués utilisés en tant qu'antagonistes du récepteur de la prostaglandine ep3 |
CA3170507A1 (fr) | 2020-02-21 | 2021-08-26 | Universiteit Maastricht | Utilisation d'un stimulateur de guanylate cyclase soluble (sgc) ou d'une combinaison d'un stimulateur de sgc et d'un activateur de sgc dans des conditions dans lesquelles le groupe heme de sgc est oxyde ou sgc est deficient en heme |
EP4110396A1 (fr) | 2020-02-26 | 2023-01-04 | Universiteit Maastricht | Combinaison thérapeutique pour le traitement de l'ischémie cérébrale et ladite combinaison thérapeutique destinée à être utilisée dans le traitement de l'ischémie cérébrale |
WO2022112213A1 (fr) | 2020-11-30 | 2022-06-02 | Bayer Aktiengesellschaft | Formes cristallines de 3-[[3-(4-chlorophényl)-5-oxo-4-((2s)-3,3,3-trifluoro-2-hydroxypropyl)-4,5-dihydro-1h-1,2,4-triazol-1-yl]méthyl]-1-[3- (trifluorométhyl)pyridin-2-yl]-1h-1,2,4-triazole-5-carboxamide |
EP4011873A1 (fr) | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Acides carboxyliques de pyrazolo pipéridine substitués |
EP4011874A1 (fr) | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Acides carboxyliques de pyrazolo pipéridine substitués |
CN115175681A (zh) | 2020-12-10 | 2022-10-11 | 拜耳公司 | sGC活化剂用于治疗眼科疾病的用途 |
AU2021393988A1 (en) | 2020-12-10 | 2023-06-22 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
EP4259618A1 (fr) | 2020-12-10 | 2023-10-18 | Bayer Aktiengesellschaft | Acides pyrazolylpipéridine carboxyliques substitués |
CN113563250B (zh) * | 2021-07-28 | 2023-07-07 | 南华大学 | 一种苯甲酸色胺衍生物及其制备与应用 |
WO2023237577A1 (fr) | 2022-06-09 | 2023-12-14 | Bayer Aktiengesellschaft | Activateurs de guanylate cyclase soluble destinés à être utilisés dans le traitement de l'insuffisance cardiaque à fraction d'éjection préservée chez les femmes |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5464853A (en) * | 1993-05-20 | 1995-11-07 | Immunopharmaceutics, Inc. | N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
US5981573A (en) * | 1996-02-07 | 1999-11-09 | Banyu Pharmaceutical Co., Ltd. | N,N-disubstituted amic acid derivatives |
TR200102561T2 (tr) * | 1999-03-01 | 2002-02-21 | Pfizer Products Inc. | Tiroid alıcı ligantları olarak oksamik asitler ve türevleri |
FR2794742B1 (fr) * | 1999-06-11 | 2005-06-03 | Sanofi Synthelabo | Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant |
-
2001
- 2001-03-07 DE DE10110750A patent/DE10110750A1/de not_active Withdrawn
-
2002
- 2002-02-22 AU AU2002234645A patent/AU2002234645A1/en not_active Abandoned
- 2002-02-22 CA CA2439756A patent/CA2439756C/fr not_active Expired - Fee Related
- 2002-02-22 EP EP02701292A patent/EP1368335A2/fr not_active Withdrawn
- 2002-02-22 WO PCT/EP2002/001891 patent/WO2002070510A2/fr active Application Filing
- 2002-02-22 JP JP2002569830A patent/JP4535679B2/ja not_active Expired - Fee Related
- 2002-02-22 US US10/469,817 patent/US20040082798A1/en not_active Abandoned
-
2006
- 2006-10-10 US US11/581,261 patent/US7705043B2/en not_active Expired - Fee Related
Non-Patent Citations (2)
Title |
---|
None * |
See also references of WO02070510A3 * |
Also Published As
Publication number | Publication date |
---|---|
WO2002070510A2 (fr) | 2002-09-12 |
US20040082798A1 (en) | 2004-04-29 |
JP4535679B2 (ja) | 2010-09-01 |
US7705043B2 (en) | 2010-04-27 |
CA2439756A1 (fr) | 2002-09-12 |
CA2439756C (fr) | 2011-01-11 |
JP2004529111A (ja) | 2004-09-24 |
AU2002234645A1 (en) | 2002-09-19 |
DE10110750A1 (de) | 2002-09-12 |
WO2002070510A3 (fr) | 2003-01-30 |
US20070179139A1 (en) | 2007-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1368335A2 (fr) | Nouveaux derives d'acide aminodicarbonique presentant des proprietes pharmaceutiques | |
EP1368300A1 (fr) | Derives d'acide aminodicarboxylique | |
EP1216225B1 (fr) | Nouveaux derives d'acide aminodicarboxylique presentant des proprietes pharmaceutiques | |
EP1216223B1 (fr) | Derives d'acide dicarboxylique a proprietes pharmaceutiques | |
EP1368302B1 (fr) | Nouveaux derives d'acide aminodicarboxylique | |
WO2001019776A2 (fr) | Nouveaux derives d'acide dicarboxylique presentant des proprietes pharmaceutiques | |
DE19943639A1 (de) | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften | |
EP1368303B1 (fr) | Derives d'acide aminodicarboxylique a substitution halogene servant d'agents pharmaceutiques pour le traitement de maladies cardio-vasculaires | |
EP1368301B1 (fr) | Derives d'acide aminodicarboxylique a halogenation de chaine laterale servant d'agents pharmaceutiques pour le traitement de maladies cardio-vasculaires | |
EP0358118A1 (fr) | Phénylamides - procédé pour leur préparation ainsi qu'un médicament contenant ces composés |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20031007 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BAYER HEALTHCARE AG |
|
RBV | Designated contracting states (corrected) |
Designated state(s): DE ES FR GB IT |
|
17Q | First examination report despatched |
Effective date: 20061027 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BAYER SCHERING PHARMA AG |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BAYER PHARMA AKTIENGESELLSCHAFT |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20110901 |